1 |
Anastasi E, Granato T, Marchei GG, et al (2010). Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumor Biol, 31, 411-5.
DOI
ScienceOn
|
2 |
Anastasi E, Marchei GG, Viggiani V, et al (2010). HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumor Biol, 31, 113-9.
DOI
ScienceOn
|
3 |
Bast Jr RC, Badgwell D, Lu Z (2005). New tumour markers: CA125 and beyond. Int J Gynecol Cancer, 15, 274-81.
DOI
ScienceOn
|
4 |
Bingle L, Singleton V, Bingle CD (2002). The putative ovarian tumor marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein is form. Ontogeny, 21, 2768-73.
|
5 |
Bolstad N, Oijordsbakken M, Nustad K (2012). Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumor Biol, 33, 141-8.
DOI
ScienceOn
|
6 |
Buamah P (2000). Benign conditions associated with raised serum CA125 concentration. J Surg Oncol, 75, 264-5.
DOI
ScienceOn
|
7 |
Escudero JM, Auge JM, Filella X, et al (2011). Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem, 57, 1534-44.
DOI
ScienceOn
|
8 |
Fuith LC, Daxenbichler G, Dapunt O (1987). CA125 in the serum and tissue of patients wth gynecological disease. Arch Gynecol Obstet, 241, 157-64.
DOI
ScienceOn
|
9 |
Hellstrom I, Hellstrom KE (2008). SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol, 622, 15-21.
DOI
|
10 |
Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al (2003). The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res, 63, 3695-700.
|
11 |
Kirchhoff C (1998). Molecular characterization of epididymal proteins. Rev Reprod, 3, 86-95.
DOI
ScienceOn
|
12 |
Malaysian Cancer Statistics - Data and Figure (2007).
|
13 |
Meden H, Fattahi-Meibodi A (1998). CA125 in benign gynecological conditions. Int J Biol Markers, 13, 231-7.
|
14 |
Menon U, Gentry-Maharaj A, Hallett R (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK collaborative trial of ovarian cancer screening (UKCTOCS). Lancet Oncol, 10, 327-40.
DOI
ScienceOn
|
15 |
Moore RG, Brown AK, Miller MC, et al (2008). The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol, 108, 402-8.
DOI
ScienceOn
|
16 |
Moore RG, McMeekin DS, Brown AK, et al (2009). A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol, 112, 40-6.
DOI
ScienceOn
|
17 |
Moore RG, Miller MC, Eklund EE, et al (2012). Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol, 206, 1-7.
DOI
ScienceOn
|
18 |
Montagnana M, Danese E, Giudici S, et al (2011). HE4 in ovarian Cancer: from discover to clinical application. Adv Clin Chem, 55, 1-20.
DOI
|
19 |
NCCLS document C28-A2. How to define and determine reference interval in the Clinical Laboratory; Approved Guideline - Second edition.
|
20 |
Niloff JM, Knapp RC, Schaetzl E, et al (1984). CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol, 64, 703-7.
|
21 |
Park Y, Kim Y, Lee EY, et al (2012). Reference ranges for HE4 and CA125 in large Asian population by automated assay and diagnostic performances for ovarian cancer. Int J Cancer, 130, 1136-44.
DOI
ScienceOn
|
22 |
Sturgeon CM, Duffy MJ (2008). National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumour markers in testicular, prostate, colorectal, breast and ovarian cancer. Clin Chem, 54, 11-79.
DOI
ScienceOn
|